SecBot SecBot
8-K ·Filed Feb 25, 2026

TDOC

Teladoc Health, Inc.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago SEC0001477449-26-000010
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The stock may react negatively to the full-year revenue decline and weak 2026 outlook for BetterHelp, despite improved profitability. Traders should monitor Integrated Care's ability to grow and whether cost discipline can offset top-line weakness. The significant cash burn ($517M) warrants attention despite positive operating cash flow.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.35
T+0 close · Feb 25, 2026 · via day close
Latest settled
+22.80%
T+60 · $6.57
Vs SPY
+14.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $5.35entry
  2. T+1 · 9mo ago −1.68%α −1.20% · $5.26
  3. T+5 · 9mo ago −4.30%α −3.14% · $5.12
  4. T+20 · 8mo ago +3.18%α +9.59% · $5.52
  5. T+60 · 6mo ago +22.80%α +14.63% · $6.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teladoc Health reported flat Q4 revenue of $642.3 million (0% YoY) and full-year 2025 revenue down 2% YoY to $2.53 billion. Net loss narrowed significantly to $200.3 million from $1.0 billion in 2024, driven by a large goodwill impairment in the prior year. Adjusted EBITDA rose 12% in Q4 but fell 10% for the full year. The company issued 2026 guidance projecting revenue of $2.47B–$2.59B and adjusted EBITDA of $266M–$308M, with Integrated Care expected to grow slightly and BetterHelp expected to decline.

Key Financial Metrics

Revenue
$2.5B
-2.0% YoY
EPS
$-1.14
Guidance
$2,470 - $2,587 million
maintained
Free Cash Flow
$166.9M

Key Facts

  • Q4 2025 revenue: $642.3M (flat YoY); Full Year 2025 revenue: $2.53B (down 2% YoY)
  • Q4 adjusted EBITDA: $83.8M (up 12% YoY); Full Year adjusted EBITDA: $281.1M (down 10% YoY)
  • Full Year 2025 net loss: $200.3M (vs. $1.0B loss in 2024), including a $71.8M goodwill impairment
  • Integrated Care segment revenue grew 3% for the year; BetterHelp revenue declined 9%
  • 2026 guidance: Revenue $2.47B–$2.59B; Adjusted EBITDA $266M–$308M; BetterHelp revenue expected to decline 0.5% to 7%
  • Cash and equivalents ended 2025 at $781.1M, down from $1.3B at end of 2024

Financial Impact

Revenue declined 2% for the full year, with EBITDA down 10%. 2026 guidance suggests continued softness, particularly in the BetterHelp segment which is expected to contract further.

revenueebitdanet incomecash

Segment Breakdown

SegmentRevenueGrowth
Integrated Care$1.6B+3.0%
BetterHelp$950.4M-9.0%

Risk Factors

  • BetterHelp segment continues to deteriorate, with revenue down 9% and guidance for further decline
  • Significant cash burn: cash balance dropped from $1.3B to $781M in one year, partly due to $551M repayment of convertible notes
  • Reliance on cost-cutting and margin improvement rather than top-line growth to drive profitability

Market Snapshot

Exchange
NYSE

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001477449-26-000010
Document: tdoc-20260225.htm0001477449-26-000010
Document: 0001477449-26-000010-index-headers.html0001477449-26-000010
Document: 0001477449-26-000010-index.html0001477449-26-000010
Document: 0001477449-26-000010.txt0001477449-26-000010

Track record

24 reports on TDOC

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +2.52% at T+1 after the Oct 28, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.60 Now $8.70 +1.22% settles Nov 17
  2. Nov 6, 202610d ago 144 Neutral 3/10 Entry $8.77 to $8.98 Now $8.70 −0.80% ▲ +2.39% +0.03% vs SPY
  3. Nov 3, 202613d ago 3 / PRESS-RELEASE Neutral 2/10 Entry $9.70 to $9.41 Now $8.70 −10.31% ▼ −2.99% +1.42% vs SPY
  4. Nov 3, 202614d ago PTAB Trial Neutral 3/10 Entry $8.89 to $9.70 Now $8.70 −2.14% ▲ +9.11% +7.46% vs SPY
  5. Oct 28, 202619d ago Press Release Bearish 6/10 No price data
  6. Oct 28, 202619d ago 8-K Bearish 6/10 Entry $8.73 to $8.51 Now $8.70 +0.34% ▲ +2.52% +0.75% vs SPY
  7. Oct 28, 202620d ago PTAB Trial Neutral 3/10 Entry $8.73 to $8.51 Now $8.70 −0.34% ▼ −2.52% −0.75% vs SPY
  8. Oct 8, 20265w ago SC 13G Neutral 3/10 Entry $5.54 to $5.77 Now $8.70 +57.04% ▲ +4.15% +3.55% vs SPY
  9. Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.09 to $5.89 Now $8.70 +42.86% ▼ −3.28% −2.54% vs SPY
  10. Sep 11, 20269w ago 144 Neutral 2/10 Entry $6.16 to $6.50 Now $8.70 +41.23% ▲ +5.52% +5.97% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026